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RESPIRATORY INFECTION
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Background: The clinical response of patients with severe acute respiratory syndrome (SARS) to a
combination of lopinavir/ritonavir and ribavirin was examined after establishing the in vitro antiviral
susceptibility of the SARS associated coronavirus to a panel of antiviral agents.
Methods: The in vitro susceptibility of the prototype of SARS associated coronavirus to a panel of
nucleoside analogues and protease inhibitors currently licensed for clinical use was studied. Forty one
patients with SARS followed for 3 weeks were treated with a combination of lopinavir/ritonavir and
ribavirin. The clinical progress and virological outcomes were monitored and compared with 111 patients
treated with ribavirin only who served as historical controls.
Results: In vitro antiviral activity against SARS associated coronavirus was demonstrated for lopinavir and
ribavirin at concentrations of 4 mg/ml and 50 mg/ml, respectively, only at 48 hours. The adverse clinical
outcome (ARDS or death) was significantly lower in the treatment group than in the historical controls
(2.4% v 28.8%, p,0.001) at day 21 after the onset of symptoms. The adverse outcome remained
significantly lower in the treatment group than in the controls—both those diagnosed early (p,0.001) and
those diagnosed later in the course of the epidemic (p = 0.002)—but there was no significant difference in
adverse outcome rates between the two time periods (p = 0.548). No time related difference in outcome
was observed in the control groups. A reduction in steroid usage and nosocomial infections was seen in
patients initially treated with lopinavir/ritonavir, and these patients had a decreasing viral load and rising
peripheral lymphocyte count. Multivariate analysis showed that age, hepatitis B carrier status, and lack of
treatment with this antiviral combination were independent predictors of an adverse outcome. Lopinavir/
ritonavir treatment was associated with a better outcome even when adjusted for baseline lactate
dehydrogenase level.
Conclusions: The apparent favourable clinical response with lopinavir/ritonavir and ribavirin supports
further randomised placebo controlled trials in patients with SARS.
S
evere acute respiratory syndrome (SARS) is caused by a
novel coronavirus.1–3 It has satisfied Koch’s postulations
for causation by its consistent isolation from patients
suffering from SARS, isolation of the virus and reproduction
of disease in non-human primates after inoculation, and the
presence of a specific antibody response against the virus in
both SARS patients and artificially infected primates.4 In an
earlier prospective study we suggested that there is an initial
viral replicative phase followed by an immunopathological
phase and end organ damage phase.5 We hypothesise that the
immunopathological response is triggered by the viral
antigen; the most strategic treatment is therefore to stop
the viral replication at the beginning so that the peak viral
load and the subsequent immunopathological damage will be
minimised. An effective antiviral treatment is therefore
required urgently. At present the treatment recommenda-
tions are largely empirical, ranging from supportive therapy
without intervention to intensive immunomodulation with
steroids. Controlled studies are difficult to perform in an
epidemic of such a life threatening condition.6 We report the
findings of an open trial of a combination of a protease




The prototype virus (HKU-39849 isolate) was used for in vitro
antiviral susceptibility testing. Initial screening was per-
formed in 96-well microtitre plates seeded with fetal rhesus
kidney-4. Doubling dilutions of antiviral agents starting at
four times the peak serum concentration after a standard
therapeutic dose down to 25% of the trough serum
concentration were tested in quadruplicate against 100
TCID50 (median tissue culture infectious dose) of SARS
coronavirus. A corresponding set tested with the drugs but
without virus challenge were used as controls. The cells were
scored for inhibition of the cytopathic effect at 48 hours. The
antiviral agents tested included acyclovir, ganciclovir, cido-
fovir, foscarnet, ribavirin, interferon a, amantadine, zidovu-
dine, stavudine, nevirapine, abacavir, ritonavir, and lopinavir.
Agents with detectable activity at the tested concentration
were re-tested in a quantitative plaque reduction assay,
followed by a chequerboard synergy test for various
combinations of the antiviral drugs. Briefly, 24-well tissue
culture plates with a confluent cell monolayer (16105 cells
per well) in 1.0 ml of minimal essential medium (MEM)
with 10% fetal calf serum (FCS) were prepared. After the
medium was aspirated, 50–100 plaque forming units (PFU)
of SARS associated coronavirus (in 1% FCS/MEM containing
the antiviral agents at appropriate concentrations) were
added to each well. Plates were incubated for 2 hours at
37 C˚ in 5% CO2. The inoculum was aspirated and 1.0 ml of
overlay (1.0% low melting point agarose in 1% FCS/MEM
with corresponding drug dilutions) was added to each well.
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Plates were further incubated for 48 hours at 37 C˚ in 5% CO2.
Cells were fixed by adding 2 ml 10% formaldehyde and the
plates were incubated at room temperature for 2 hours. The
agarose plugs were aspirated and each well was stained with
0.5% crystal violet prepared in 70% methanol. The viral
plaques were counted. A chequerboard assay of inhibition of
the cytopathic effect by the combination of ribavirin and
lopinavir was performed using 25, 50, and 100 TCID50 per
well in 96-well microtitre plates.
Clinical study
Between 24 March and 28 April 2003, 152 consecutive
patients with probable SARS (according to the World Health
Organisation definition) admitted to the United Christian
Hospital and Caritas Medical Centre were recruited to the
study after approval by the ethics committees. Once the
diagnosis of SARS was established, ribavirin was given for
14 days (4 g oral loading dose followed by 1.2 g every
8 hours, or 8 mg/kg intravenously every 8 hours if the
patient could not tolerate oral treatment) with a reducing
regimen of corticosteroid for 21 days (starting dose: hydro-
cortisone 100–200 mg every 6–8 hours or methylpredniso-
lone 3 mg/kg/day). Pulses of intravenous methylprednisolone
(0.5–1 g/day up to 4 g) were used if patients developed
increasing shortness of breath, oxygen desaturation, or
radiological worsening.7
Patients treated before 16 April 2003 served as historical
controls (n = 111). The clinical features and virological
findings of the first 75 cases have been reported previously.5
After 16 April 2003, newly diagnosed SARS patients and
patients who had not developed acute respiratory distress
syndrome (ARDS) were started on a combination of lopinavir
(400 mg)/ritonavir (100 mg) orally every 12 hours for
14 days (n = 41) after obtaining informed consent (ritonavir
inhibits the CYP3A mediated metabolism of lopinavir and
thereby potentiates the serum level of lopinavir).
Both the historical controls and the lopinavir/ritonavir
treated group were given ribavirin and corticosteroid accord-
ing to the same protocol. The primary outcome measure was
a composite adverse outcome at 21 days, which was defined
as severe hypoxaemia (meeting the ARDS criteria of arterial
oxygen tension (PaO2) to fraction of inspired oxygen (FiO2) of
,200 mm Hg8) or death. The treatment group was divided
into two subgroups for further analyses. In the ‘‘initial
treatment’’ subgroup (n = 12) lopinavir/ritonavir was started
before pulse methylprednisolone (median time from onset of
symptoms 3.5 days), while in the ‘‘rescue treatment’’
subgroup (n = 29) lopinavir/ritonavir was started after pulse
methylprednisolone (median time from onset of symptoms
14 days). Clinical measurements and blood tests were
performed daily.
Diagnosis of coronavirus infection was made from naso-
pharyngeal swabs on admission and convalescent serum on
days 14–28 after onset of symptoms. In six randomly selected
patients in the initial treatment subgroup and 12 historical
controls with initially positive nasopharyngeal specimens for
coronavirus tested by reverse transcriptase polymerase chain
reaction (RT-PCR), quantitative RT-PCR was performed
serially on days 5, 10, 15, and 20 after onset of symptoms.
Stools were collected from all 41 patients in the treatment
group for RT-PCR analysis at days 7, 14, and 21. The
virological diagnostic protocol and other microbiological
work up was performed in the same way as in our previous
publications.1 5
Statistical analysis
All time related data were calculated from the day of
symptom onset. The baseline characteristics of the historical
controls and the treatment group were compared by Fisher’s
exact test for categorical variables, Student’s t test, or Mann-
Whitney U test for continuous variables where appropriate.
The Kruskal-Wallis test was used to compare the cumulative
doses of methylprednisolone in the various treatment
subgroups. As this was an open non-randomised study, an
imbalance in the baseline characteristics of the two groups
was expected. To adjust for this imbalance, factors that were
identified on univariate analysis to be associated with an
adverse outcome at 21 days were analysed by multiple logistic
regression with forward selection to identify independent
predictive factors. In addition, the odds ratio for lopinavir/
ritonavir treatment with respect to the primary outcome was
adjusted for the baseline lactate dehydrogenase (LDH) level
by multiple logistic regression, based on an a priori assump-
tion that LDH might affect the outcome. As lopinavir/ritonavir
was used later in the course of the epidemic, it was possible that
any apparent benefit seen might be due to the experience
gained by medical staff in treating the patients or attenuation of
the virus during the epidemic. To determine whether there was
a time related difference in outcome, the historical control
group was divided into two subgroups according to admission
date (an earlier and a later period) for further analyses. The date
of division was arbitrarily chosen to achieve a reasonable
balance of number of cases across the subgroups. The outcome
of the two historical subgroups and the treatment group was
compared using the x2 test. A two tailed p value of ,0.05 was
considered significant. SPSS Version 11.0 (SPSS Inc, Chicago,
IL, USA) was used for all analyses.
RESULTS
In vitro antiviral susceptibility testing showed that the
cytopathic effect of the SARS coronavirus was inhibited by
lopinavir at 4 mg/ml and ribavirin at 50 mg/ml after 48 hours
of incubation (fig 1). The inhibitory effect had worn off at
96 hours. None of the other drugs tested had any inhibitory
effect. The results were confirmed by plaque reduction assay.
Using the chequerboard assay for synergy, inhibition of the
cytopathic effect was achieved down to a concentration of
lopinavir 1 mg/ml combined with ribavirin 6.25 mg/ml only
when the viral inoculum was reduced to 50 TCID50 or below.
The baseline characteristics and outcomes of the historical
controls and the treatment group are shown in table 1.The
152 patients had a mean (SD) age of 41.4 (14.8) years and
there were 58 (38.2%) men. 96.7% had virologically con-
firmed SARS associated coronavirus. Among the historical
controls, 25 (22.5%) met the ARDS criteria of hypoxaemia
Figure 1 Dose dependent antiviral effects of ribavarin and lopinavir on
SARS coronavirus. In vitro antiviral susceptibility testing showed that the
cytopathic effect was inhibited by lopinavir at 4 mg/ml and ribavirin at
50 mg/ml after 48 hours of incubation.
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and seven (6.3%) had died by day 21. In the treatment group
only one patient (2.4%) met the ARDS criteria for hypox-
aemia and there were no deaths. The 21 day adverse outcome
rate was therefore 28.8% for the historical controls and 2.4%
for the treatment group, giving an effect size of 26.4% (95%
confidence interval 16.8 to 36.0, p,0.001) for lopinavir/
ritonavir treatment.
There was no significant difference between the two
groups with respect to age and co-morbidity. However, the
treatment group had fewer men, a higher initial platelet
count, and lower initial LDH levels. Two models of multiple
logistic regression were used to asses whether lopinavir/
ritonavir treatment was independently associated with
improved outcome. In the first model, multiple logistic
regression with forward selection showed that age
(p = 0.013), chronic hepatitis B infection (p = 0.007), and
lack of lopinavir/ritonavir treatment (p = 0.011) were inde-
pendently associated with the 21 day adverse outcome
(table 2). In the second model, the odds ratio of lopinavir/
ritonavir treatment was adjusted for the LDH level by
multiple logistic regression, based on the a priori assumption
that LDH might confound the outcome. Lopinavir/ritonavir
treatment was found to be associated with a significantly
better outcome (p = 0.014), despite adjustment for the LDH
level (table 3).
To determine whether there was a time related difference
in outcome, the control group was divided into two
subgroups according to the date of admission. Period 1 was
from 24 March to 27 March 2003 (4 days, n = 68) and period
2 was from 28 March to 15 April 2003 (19 days, n = 43). The
dates were chosen to achieve a reasonable balance in the
number of cases in each subgroup. Lopinavir/ritonavir was
used for patients admitted between 16 April and 28 April
(13 days, n = 41). The treatment group had a significantly
better 21 day outcome than the two control subgroups with
only one patient (2.4%) developing ARDS and no deaths
(p,0.001 v period 1, p = 0.002 v period 2, x2 test), but the
21 day outcome rate did not differ significantly between the
two time periods in the historical control group (21 (30.9%)
developed ARDS or died within 21 days in period 1 compared
with 11 (25.6%) in period 2, p = 0.548, x2 test).
The viral load in the nasopharyngeal swabs showed a
progressive decrease in the initial treatment subgroup. A
consistent decrease in the geometric mean viral load from 4.7
6104 copies per ml on day 5 to an undetectable level on day
10 was seen in five out of six randomly selected patients
(fig 2A). Case 6 had a transient decrease in viral load at day
10 followed by a rebound at day 15. This was associated with
the use of pulse methylprednisolone on day 7. In contrast, 12
randomly selected patients from the historical control group
showed an inverted V-shaped curve, with a geometric mean
peak viral load of 1.9 6 107 copies per ml at day 10 which
remained detectable (geometric mean 6.3 6 103 copies per
ml) in 10 patients at day 20 (fig 2B). The stool RT-PCR
positivity rate at day 21 was 2.4% for the treatment group and
67% for the historical controls.5
With regard to the progression of disease symptomatology
in the treatment group compared with the historical controls,
Table 1 Baseline characteristics and 21 day adverse outcome (death or development of




(n = 41) p value
Mean (SD) age (years) 42.1 (14.7) 39.4 (15.2) 0.32
Male:female ratio 48:63 10:31 0.039
Active co-morbid condition 22 (19.8%) 6 (14.6%) 0.464
Chronic hepatitis B infection 11 (9.9%) 1 (2.4%) 0.182
Mean (SD) duration of symptoms to admission (days) 2.61 (2.3) 1.85 (1.5) 0.05
Apparently normal chest radiograph on admission 23 (20.7%) 11 (26.8%) 0.511
Multilobar involvement on initial chest radiograph 29 (26.1%) 5 (12.2%) 0.081
NPA RT-PCR positive at diagnosis 41 (36.9%) 14 (34.1%) 0.850
Mean (SD) haemoglobin (g/dl) 13.3 (1.6) 13.5 (1.4) 0.468
Mean (SD) initial total peripheral WBC count (6109/l) 6.4 (2.2) 6.7 (3.0) 0.420
Mean (SD) initial lymphocyte count (6109/l) 1.0 (0.5) 0.9 (0.3) 0.297
Mean (SD) initial platelet count (6109/l) 169 (44) 199 (77) 0.023
Median (IRQ) initial LDH (IU/l) 401 (344–467) 276 (197–336) ,0.001
Median (IRQ) cumulative pulse methylprednisolone
dose (g)
1.5 (1.0–3.0) 2.0 (0–3.0) 0.477
Development of ARDS or death within 21 days 32 (28.8%) 1 (2.4%) ,0.001
Death/ARDS at day 21 7 (6.3%)/25 (22.5%) 0 (0%)/1 (2.4%) –
NPA = nasopharyngeal aspirate; WBC = white blood cell; LDH = lactate dehydrogenase; ARDS = acute respiratory
distress syndrome.
Table 2 Independent risk factors predicting adverse
outcome of death or development of acute respiratory




(95% CI) p value
Age group (years) 0.013
21–40 1.00 –
41–60 1.49 (0.56 to 3.98) 0.431
61+ 4.69 (1.57 to 13.97) 0.006
HBsAg positive patients 6.35 (1.67 to 24.08) 0.007
Treatment
Controls 1.00 –
Treatment group 0.07 (0.01 to 0.55) 0.011
HBsAg = Hepatitis B surface antigen.
Table 3 Adjustment of odds ratio of lopinavir/ritonavir
treatment for lactate dehydrogenase (LDH) level with
respect to the adverse outcome of death or development
of acute respiratory distress syndrome (ARDS) requiring
intensive care within 21 days
Variables
Adjusted odds ratio
(95% CI) p value
Treatment
Controls 1.000 –
Treatment group 0.076 (0.01 to 0.589) 0.014
LDH level (per 100 IU/l
increase)
1.155 (0.953 to 1.401) 0.142
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diarrhoea (24.4% v 62.2% p,0.001), recurrent fever (39% v
60.4% p = 0.0027), and worsening of the chest radiograph
(51.2% v 81.1% p,0.001) occurred with reducing frequencies.
The serial lymphocyte counts showed a rising trend in the
initial treatment subgroup from 1.2 (0.7) 6 109/l on
admission to 1.0 (0.6) 6 109/l, 1.3 (0.9) 6 109/l, and 1.9
(1.1)6109/l on days 7, 14 and 21 respectively, whereas in the
historical control group the lymphocyte counts fell progres-
sively from 1.1 (0.7)6109/l on admission to 0.9 (0.1)6109/l,
0.7 (0.1)6 109/l, and 0.5 (0.4)6 109/l on days 7, 14 and 21,
respectively.
The cumulative pulse methylprednisolone dose did not
differ between the historical controls and the treatment
group (table 1). However, in the subgroup analyses the initial
treatment subgroup required a significantly lower cumulative
dose of pulse methylprednisolone than the rescue treatment
subgroup and historical controls (median 0 g, 2.5 g, and 1.5 g
respectively; p,0.001). There were also significantly fewer
patients who suffered from nosocomial infections (0%) in the
initial treatment subgroup than in the rescue treatment
subgroup (27.6%) and historical control group (25.2%;
p = 0.043 and p = 0.048, respectively). Patients with nosoco-
mial infections received a higher mean (SD) cumulative dose
of pulse methylprednisolone (2.6 (1.6) g) than those free of
nosocomial infection (1.8 (1.5) g; p = 0.009).
Mild adverse reactions were experienced by 11 patients
(26.8%) in the treatment group: gastrointestinal upset
(n = 11), liver dysfunction (n = 7), headache (n = 6), blurred
vision (n = 3). Only one patient required early discontinua-
tion because of a significant rise in alanine aminotransferase
(ALT) to more than twice the normal level. A fall in
haemoglobin of more than 2 g/dl occurred in 29 patients
(70.7%) in the treatment group, two of whom required a
transfusion; 11 patients (26.8%) had asymptomatic brady-
cardia at a mean (SD) of 42 (6) beats per minute during the
study period, which was similar to the historical controls.
DISCUSSION
In the early stages of the SARS epidemic before identification
of the causal agent, histopathological changes in open lung
biopsy specimens suggested the possibility of immunopatho-
logical damage.9 A broad spectrum antiviral agent (ribavirin)
and immunosuppressive doses of steroids were therefore
used as the empirical treatment. After the SARS associated
coronavirus was isolated, in vitro antiviral susceptibility
testing suggested that the virus could only be inhibited
transiently by very high concentrations of ribavirin, levels
difficult to achieve clinically. There was therefore an urgent
need to find an alternative treatment. Our previous study on
the sequential changes in viral load and disease progression
suggested that there is an initial viral replicative phase which
peaks at around day 10. This implies that there is a
therapeutic window that could be exploited, provided an
active antiviral agent was available. The key strategy in the
treatment of SARS was therefore to find an effective antiviral
agent that would decrease the peak viral load and thus the
associated degree of immunopathological damage. This
would decrease the need for immunosuppressants which
were often associated with an increased risk of nosocomial
infections, especially in patients who required mechanical
ventilation.
Both the peak (9.6 mg/ml) and trough (5.5 mg/ml) serum
concentrations of lopinavir can just reach the inhibitory
concentration against the SARS virus.10 However, oral
lopinavir/ritonavir may achieve a high fecal concentration
because 20% of the drug is found unchanged in the stool.11 In
our previous study we found that severe watery diarrhoea
was a prominent feature in 73% of the SARS patients, and a
high rate of fecal shedding was detected by RT-PCR between
days 10 and 21.5 The gastrointestinal mucosa might therefore
be an important reservoir for viral replication and dissemina-
tion. Although we may not achieve a satisfactory serum
inhibitory concentration, the intestinal mucosa concentration
may be high enough to stop viral replication at this site.
Because of the non-randomised nature of this open study,
there were differences between the treatment and historical
control group in terms of sex, platelet counts, and LDH
levels. However, there was no significant difference between
the two group with respect to age and co-morbidity, two
important prognostic factors found in the previous study.5 12–15
On multivariate analysis, lopinavir/ritonavir treatment was
an independent factor associated with improved 21 day
outcome and this remained after adjustment for the LDH
level. The 21 day adverse outcome rate of 2.4% for the
treatment group compares favourably not only with our
historical controls, but also with the reported figures of 21–
23.3%12 13 and the projected figures of 13–43% for various age
groups.16
Patients with SARS treated with lopinavir/ritonavir
appeared to run a milder disease course in terms of diarrhoea,
recurrence of fever, and worsening of chest radiographs. A
reduction in the viral load was also seen (fig 2A). The viral
load showed a progressive decrease in the initial treatment
subgroup, in contrast to the expected inverted V-shaped
curve previously reported.5 Moreover, the stool RT-PCR
positivity rate at day 21 in the treatment group (2.4%) was
markedly lower than that previously reported for the
historical controls (67%).5 These findings suggest that the
benefit of the combination was at least partly related to
the antiviral activity.
In terms of adverse effects, there was little difference
between the historical control group and that reported in the
Figure 2 (A) Change in viral load by sequential quantitative RT-PCR for
SARS associated coronavirus in nasopharyngeal swabs of six patients in
the initial treatment subgroup. Note that case 6 was given pulse
methylprednisolone on day 7. (B) Change in viral load by sequential
quantitative RT-PCR for SARS associated coronavirus in nasopharyngeal
swabs of 12 patients in the historical control group.
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literature for lopinavir/ritonavir.11 It is important to note that
the dose of ribavirin used in SARS is much lower than that
used in the treatment of haemorrhagic fever. Thus, very few
patients had their treatment terminated or suffered from
major side effects except for anaemia. Furthermore, a fall in
haemoglobin of 1.3 g/dl at a mean of 6.4 days was also found
in a local cohort of patients with community acquired
pneumonia (unpublished data).
As this is not a randomised study, there could be a few
alternative interpretations of the results. Firstly, it is reason-
able to suspect that the dramatic improvement in outcome in
the treatment group could be due to the gain in experience in
the management later in the epidemic. Attenuation of the
virus during the course of an epidemic is another theoretical
possibility to explain the improved outcome. Nevertheless, re-
analysis of the historical controls, divided into subgroups
according to an earlier and a later time of admission, did not
change the conclusion that the treatment group had a better
outcome than the controls in both periods. Moreover, there
was no difference in the outcome between the two historical
periods, suggesting that the period of admission was probably
not the major reason for the apparent improved outcome in
the lopinavir/ritonavir treatment group.
Secondly, corticosteroid use might confound the outcome
as it might blunt the host response and promote viral
replication. However, both the historical controls and the
treated patients were put on the same protocol of corticoster-
oid treatment and the cumulative methylprednisolone dose
did not differ between the two groups as a whole. The
improved outcome in the treatment group was therefore not
the result of reduced steroid use. In subgroup analysis,
patients who received lopinavir/ritonavir as the initial
treatment seemed to run a milder disease course and had a
reduction in the viral load. Their need for rescue pulse
methylprednisolone for severe respiratory deterioration was
therefore reduced. Lopinavir/ritonavir might have improved
the outcome either by a direct effect on the viral load or by an
indirect steroid sparing effect because of a reduction in
immunopathological damage.
Thirdly, the apparent improved outcome in the treatment
group could be a result of a worse than expected outcome in
the historical control group. Opponents of ribavirin and
steroids have suggested that, in the USA where supportive
treatment alone was used to treat SARS, the case fatality rate
was zero.17 However, it is noteworthy that, in the USA, only
eight out of 47 probable cases and none of the 162 suspected
cases have had virological confirmation of SARS coronavirus
infection.18 In contrast, in China, Taiwan, Canada, and
Singapore there were 5327, 665, 251, and 238 cases of
SARS, respectively, and case fatality rates of 7%, 27%, 17%,
and 14% were reported.17
The use of high dose steroid treatment in SARS is, at best,
controversial. Advocates for high dose steroid use have noted
anecdotal successes of pulse methylprednisolone in SARS at
doses used for the treatment of organ rejection.19 The same
group of researchers investigated the response of patients
with SARS to different steroid regimens and concluded that
high dose pulse methylprednisolone therapy (organ rejection
treatment range) appeared to be more efficacious and equally
safe as a lower dose regimen.20 However, another group has
not been able to show that the use of pulse steroid is
associated with a better outcome.15 These findings need to be
tested in randomised, placebo controlled studies which
should include an arm not using steroids or antiviral agents.
In view of the apparent reductions in the composite
adverse outcome at day 21, the viral load, the steroid dose,
and the incidence of nosocomial infections, a randomised,
placebo controlled study is justified to test the benefit of
lopinavir/ritonavir in SARS. We propose that the combination
of lopinavir/ritonavir and ribavirin should be tested against
lopinavir/ritonavir alone and placebo.
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